NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00720512,Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab,https://clinicaltrials.gov/study/NCT00720512,BEBYP,TERMINATED,"RATIONALE: Drugs used in chemotherapy, such as irinotecan, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether combination chemotherapy is more effective with or without bevacizumab in treating metastatic colorectal cancer.

PURPOSE: This randomized phase III trial is studying second-line combination chemotherapy to see how well it works compared with or without bevacizumab in treating patients with metastatic colorectal cancer who have received first-line chemotherapy and bevacizumab.",NO,Colorectal Cancer,BIOLOGICAL: bevacizumab|DRUG: fluorouracil|DRUG: irinotecan hydrochloride|DRUG: leucovorin calcium|DRUG: oxaliplatin,"Progression-free survival, last progression of the last patient","Overall survival, the end of the stady|Response rate, last visit of the last patient|Safety, the end of the study",,Gruppo Oncologico del Nord-Ovest,,ALL,"ADULT, OLDER_ADULT",PHASE3,184,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CDR0000598567|GONO-BEBYP-ASL607LIOM03|GONO-AIFA - FARM5C4FB4|EUDRACT:2007-002886-11,2008-06,2013-02,2014-03,2008-07-22,,2015-03-11,"Universita Politecnica Delle Marche, Ancona, 60100, Italy|Azienda Usl 8 Arezzo, Arezzo, 52100, Italy|Ospedale degli Infermi - ASL 12, Biella, 13900, Italy|A. Perrino Hospital, Brindisi, 72100, Italy|Azienda Ospedaliera S. Elia, Caltanissetta, 93100, Italy|Ospedale Santa Croce, Cuneo, 12100, Italy|Ospedale San Giuseppe, Empoli, 50053, Italy|Ospedale E. Profili, Fabriano, 60044, Italy|Ospedale Civile S. Croce, Fano, 61032, Italy|Azienda Ospedaliera di Firenze, Florence, 50011, Italy|Azienda Ospedaliero Careggi, Florence, 50139, Italy|Istituto Nazionale per la Ricerca sul Cancro, Genoa, 16132, Italy|Ospendale S. Andrea EST, La Spezia, 19100, Italy|Azienda Ospedaliera Vito Fazzi, Lecce, 73100, Italy|Azienda USL12 Versilia, Lido di Camaiore, 55043, Italy|Ospedale Campo Di Marte Lucca, Lucca, 55100, Italy|Azienda Ospedaliera Maggiore Della Carita, Novara, 28100, Italy|Azienda Ospedaliera Pisana, Pisa, 56126, Italy|Arcispedale S. Maria Nuova, Reggio Emilia, 42100, Italy|Azienda Ospedaliera Universitaria Senese, Siena, 53100, Italy|Dipartimento Oncologico, Siena, 53100, Italy",
